<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05089279</url>
  </required_header>
  <id_info>
    <org_study_id>A111_01BE2019</org_study_id>
    <nct_id>NCT05089279</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Pharmacokinetics of CKD-349</brief_title>
  <official_title>An Open Label, Randomized, Single-dose, 2-sequence, 2-period, Cross-over Phase 1 Study to Evaluate the Safety and Pharmacokinetics of CKD-349 in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to Evaluate the Safety and Pharmacokinetics of CKD-349&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An Open Label, Randomized, Single-dose, 2-sequence, 2-period, Cross-over Phase 1 Study to&#xD;
      Evaluate the Safety and Pharmacokinetics of CKD-349 in Healthy Adult Volunteers&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 20, 2021</start_date>
  <completion_date type="Anticipated">December 6, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 29, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt of CKD-349</measure>
    <time_frame>0, 0.08, 0.17, 0.33, 0.5, 0.67, 0.83, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 hours</time_frame>
    <description>AUCt: Area under the concentration-time curve from time zero to time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of CKD-349</measure>
    <time_frame>0, 0.08, 0.17, 0.33, 0.5, 0.67, 0.83, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Cmax: Maximum plasma concentration of the drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf of CKD-349</measure>
    <time_frame>0, 0.08, 0.17, 0.33, 0.5, 0.67, 0.83, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Area under the concentration-time curve from zero up to ∞</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of CKD-349</measure>
    <time_frame>0, 0.08, 0.17, 0.33, 0.5, 0.67, 0.83, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Time to maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt/AUCinf of CKD-349</measure>
    <time_frame>0, 0.08, 0.17, 0.33, 0.5, 0.67, 0.83, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 hours</time_frame>
    <description>AUCt/AUCinf</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of CKD-349</measure>
    <time_frame>0, 0.08, 0.17, 0.33, 0.5, 0.67, 0.83, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 hours</time_frame>
    <description>Terminal elimination half-life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: D113/ Period 2: CKD-349</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-349/ Period 2: D113</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D113</intervention_name>
    <description>QD, PO</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-349</intervention_name>
    <description>QD, PO</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult volunteers aged ≥ 19 years&#xD;
&#xD;
          2. Weight ≥50kg (man) or 45kg (woman), with calculated body mass index (BMI) of 18 to 30&#xD;
             kg/m2&#xD;
&#xD;
          3. Those who have no congenital diseases or chronic diseases and have no abnormal&#xD;
             symptoms or findings.&#xD;
&#xD;
          4. Those who are eligible for clinical trials based on laboratory (hematology, blood&#xD;
             chemistry, serology, urology) and 12-lead ECG results at screening.&#xD;
&#xD;
          5. Those who agree to contraception until 7 days after clinical trial.&#xD;
&#xD;
          6. Individuals who voluntarily decide to participate and agree to comply with the&#xD;
             cautions after fully understand the detailed description of this clinical trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Those who have clinically significant diseases or history in digestive systems,&#xD;
             cardiovascular system, endocrine system, respiratory system, blood·tumor, infectious&#xD;
             disease, kidney and urogenital system, mental·nervous system, musculoskeletal system,&#xD;
             immune system, otolaryngology, skin system, ophthalmology system, etc.&#xD;
&#xD;
          2. Those who have a history of gastrointestinal surgery except simple appendectomy and&#xD;
             hernia surgery.&#xD;
&#xD;
          3. Those who take barbiturate and any related drugs which may cause induction or&#xD;
             inhibition of drug metabolism within 1 month before the first administration of&#xD;
             investigational products or take drugs that may interfere with this clinical trials&#xD;
             within 10 day before the first administration&#xD;
&#xD;
          4. Those who received investigational products or participated in bioequivalence tests&#xD;
             within 6 months before the first administration of clinical trial drugs.&#xD;
&#xD;
          5. Those who donated whole blood within 8 weeks or donated ingredients within 2 weeks, or&#xD;
             received a blood transfusion within 4 weeks.&#xD;
&#xD;
          6. Those who exceed an alcohol and cigarette consumption than below criteria A. Alcohol:&#xD;
             Man- 21 glasses/week, Woman - 14 glasses/week (1 glass: Soju 50mL, Wine 30mL, or beer&#xD;
             250mL) B. Smoking: 20 cigarettes/day&#xD;
&#xD;
          7. Those who overreacts to the ingredient of this drug and is administering an&#xD;
             angiotensin conversion enzyme (ACE) inhibitor or has not passed 36 hours since&#xD;
             discontinuation of administration and has a history of vascular edema when&#xD;
             administering an angiotensin conversion enzyme (ACE) inhibitor or an angiotensin&#xD;
             receptor antagonist (ARB).&#xD;
&#xD;
          8. Those who are deemed insufficient to participate in this clinical study by&#xD;
             investigators.&#xD;
&#xD;
          9. Woman who are pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yook-Hwan Noh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yook-Hwan Noh</last_name>
    <phone>82-70-4665-9174</phone>
    <email>m3191@newyjh.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>H Plus Yangji Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Gwanak-gu</state>
        <zip>08779</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 14, 2021</study_first_submitted>
  <study_first_submitted_qc>October 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

